Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AL-38583 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AL-38583 0.01% | EXPERIMENTAL | AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks |
| AL-38583 0.05% | EXPERIMENTAL | AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks |
| AL-38583 0.2% | EXPERIMENTAL | AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks |
| AL-38583 Vehicle | PLACEBO_COMPARATOR | AL-38583 ophthalmic solution vehicle, 1 drop instilled in each eye 3 times per day for 2 weeks |
| MAXIDEX | ACTIVE_COMPARATOR | Dexamethasone ophthalmic suspension, 0.1%, 1 drop instilled in each eye 3 times per day for 2 weeks |
| Name | Type | Description |
|---|---|---|
| AL-38583 ophthalmic solution | DRUG | - |
| AL-38583 ophthalmic solution vehicle | DRUG | Inactive ingredients used as a placebo comparator |
| Dexamethasone ophthalmic suspension, 0.1% | DRUG | - |
Inclusion Criteria: * Presence of signs and symptoms of ocular inflammation in both eyes. * Have a positive CAC response at Visit 1. * Able to avoid the use of disallowed medications as well as contact lens wear for the specified period prior to Visit 1, and for the duration of the study. * Other p...
AL-38583 is an investigational small molecule being developed for the treatment of allergic conjunctivitis. It is formulated as an ophthalmic solution and is intended to address inflammation associated with this condition. The drug is currently in clinical development and has not been approved by regulatory authorities.
AL-38583 is being developed by Alcon Inc., a company traded on the New York Stock Exchange under the ticker symbol ALC. Alcon is conducting clinical research on this ophthalmic solution for allergic conjunctivitis.
AL-38583 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval. The Phase 2 trial for this ophthalmic solution has been completed, and the drug remains under investigation for allergic conjunctivitis.
AL-38583 has one completed Phase 2 clinical trial registered as NCT01001091, titled "AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation." This randomized, double-blind, placebo-controlled study enrolled 312 participants aged 18 years and older with allergic conjunctivitis.
AL-38583 is a small molecule formulated as an ophthalmic solution for allergic conjunctivitis. The specific molecular target of AL-38583 has not been disclosed, so its precise mechanism of action is not publicly detailed. It is being studied for its ability to address inflammation associated with allergic conjunctivitis.